Advanced Search

    Technical Analysis for NRXP - NeuroRx, Inc.

    Grade Last Price % Change Price Change
    C 1.25 -2.34% -0.03
    NRXP closed down 2.34 percent on Thursday, January 26, 2023, on 19 percent of normal volume. It was able to find support at its 50 day moving average.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical NRXP trend table...
    Date Alert Name Type % Chg
    MACD Bearish Signal Line Cross Bearish 0.00%
    20 DMA Support Bullish 0.00%
    50 DMA Support Bullish 0.00%
    NR7 Range Contraction -2.34%
    Narrow Range Bar Range Contraction -2.34%
    Inside Day Range Contraction -2.34%
    Pocket Pivot Bullish Swing Setup -2.34%
    Wide Bands Range Expansion -2.34%
    NR7 Range Contraction -0.79%
    Wide Bands Range Expansion -0.79%
    Older End-of-Day Signals for NRXP ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    50 DMA Support about 20 hours ago
    Down 5% about 20 hours ago
    Fell Below 50 DMA about 20 hours ago
    Fell Below Previous Day's Low about 20 hours ago
    60 Minute Opening Range Breakdown about 20 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators Basic chart:

    Profile

    NeuroRx, Inc. operates as a clinical stage-small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders. Its drug candidate includes Cyclurad, an oral therapeutic for the treatment of acute/elevated suicidal ideation/crisis in bipolar depression. The company was incorporated in 2015 and is headquartered in Wilmington, Delaware.
    Classification
    Sector: Industrials
    Industry: Conglomerates
    Keywords: Life Sciences Health Sciences Health Care Central Nervous System Disorders Antidepressants Bipolar Disorder Treatment Of Central Nervous System Disorders Atypical Antipsychotics Bipolar Depression

    Is NRXP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 19 NRx Pharma gains on FDA comments regarding lead asset
    Jan 19 NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
    Jan 5 NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
    Jan 5 NRx Pharmaceuticals: A Speculative, Binary Play
    Jan 3 NRx Pharma gains as Phase 3 trial for bipolar candidate starts
    Jan 3 NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted
    Dec 20 Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements
    Dec 5 NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
    Dec 2 NRx Receives Nasdaq Notice of Listing Compliance
    Nov 30 Mawson Infrastructure, NRx Pharmaceuticals And This Penny Stock Insiders Are Aggressively Buying
    See more NRXP news...

    Indicators

    Indicator Value
    52 Week High 3.54
    52 Week Low 0.4899
    Average Volume 410,117
    200-Day Moving Average 0.98
    50-Day Moving Average 1.21
    20-Day Moving Average 1.23
    10-Day Moving Average 1.29
    Average True Range 0.10
    RSI 51.92
    ADX 23.53
    +DI 18.67
    -DI 15.39
    Chandelier Exit (Long, 3 ATRs) 1.11
    Chandelier Exit (Short, 3 ATRs) 1.34
    Upper Bollinger Bands 1.40
    Lower Bollinger Band 1.06
    Percent B (%b) 0.56
    BandWidth 27.80
    MACD Line 0.03
    MACD Signal Line 0.03
    MACD Histogram -0.0018
    Fundamentals Value
    Market Cap 3.36 Million
    Num Shares 2.69 Million
    EPS 0.02
    Price-to-Earnings (P/E) Ratio 56.82
    Price-to-Sales 0.00
    Price-to-Book 9.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.37
    Resistance 3 (R3) 1.37 1.32 1.35
    Resistance 2 (R2) 1.32 1.29 1.33 1.34
    Resistance 1 (R1) 1.29 1.27 1.27 1.29 1.34
    Pivot Point 1.24 1.24 1.23 1.25 1.24
    Support 1 (S1) 1.21 1.21 1.19 1.21 1.16
    Support 2 (S2) 1.16 1.19 1.17 1.16
    Support 3 (S3) 1.13 1.16 1.15
    Support 4 (S4) 1.13